Society

EQS-News: Aurubis AG: Focus on recycling: Aurubis makes the final round of the 15th German Sustainability Award

Retrieved on: 
Saturday, December 3, 2022

Dsseldorf, December 2, 2022: In the presence of German Chancellor Olaf Scholz, the winners of the 15th German Sustainability Award 2023 were announced at a gala event in Dsseldorf on Friday night.

Key Points: 
  • Dsseldorf, December 2, 2022: In the presence of German Chancellor Olaf Scholz, the winners of the 15th German Sustainability Award 2023 were announced at a gala event in Dsseldorf on Friday night.
  • Being named a finalist for this important award is confirmation that we are on the right track in the area of sustainability.
  • It is also an incentive to continue to do our utmost to expand our industry leadership in the area of sustainability, Aurubis CEO Roland Harings says.
  • This year marks the 15th German Sustainability Award (DNP), Europes highest award for commitment to the environment and social responsibility.

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Friday, December 2, 2022

Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.

Key Points: 
  • Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.
  • In-person and virtual meetings may be scheduled directly with Molecular Templates.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

MFG Chemical Wins Four Performance Improvement Awards

Retrieved on: 
Friday, December 2, 2022

MFG Chemical, a leader in specialty and custom chemical manufacturing, has won four Awards for plant safety and performance improvement from the chemical industry association SOCMA (Society of Chemical Manufacturers Association).

Key Points: 
  • MFG Chemical, a leader in specialty and custom chemical manufacturing, has won four Awards for plant safety and performance improvement from the chemical industry association SOCMA (Society of Chemical Manufacturers Association).
  • View the full release here: https://www.businesswire.com/news/home/20221202005442/en/
    MFG Chemical receives four (4) Performance Improvement Awards from the Society of Chemical Manufacturers & Affiliates (SOCMA) for the safety, capacity expansions and efficiency improvements made at MFG's custom chemical manufacturing plants.
  • Standing from left to right are SOCMA Executive Committee Chair Mike Ott, MFG Chemical VP EHS&S Joe Welch , MFG Chemical VP R&D Guido DeStefano, and SOCMA President & CEO Jennifer Abril.
  • According to MFG Chemical President & CEO Paul Turgeon, We are very proud of the MFG Chemical team and its total dedication to plant safety and continuous performance improvement.

Global Dermatology Medical Lasers Market 2022 to 2031 - Featuring Cynosure, Miracle Laser, Syneron and Shenzhen GSD Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

Major players in the dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sincoheren, Fotona, Alma Lasers Ltd, and Cutera.

Key Points: 
  • Major players in the dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sincoheren, Fotona, Alma Lasers Ltd, and Cutera.
  • The dermatology medical lasers market consists of sales of dermatology medical lasers and related services by companies that manufacture them.
  • The main devices of dermatology medical lasers are surgical lasers and vascular lasers.
  • Therefore, the use of picosecond lasers in dermatological processes is expected to be the new trend in the dermatology medical lasers market.

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

Retrieved on: 
Friday, December 2, 2022

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.

Key Points: 
  • OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.
  • Smidt - Centre for Human Drug Research, Leiden, the Netherlands
    For more information, please visit the Congress website, here .
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion

Retrieved on: 
Friday, December 2, 2022

NEW YORK, Dec. 2, 2022 /PRNewswire/ -- Cure Brain Cancer Foundation CEO Lance Kawaguchi rang the bell to open trading on the Nasdaq stock exchange on Friday morning, December 2. The Foundation announced the establishment of an independent U.S. affiliate that will widely increase the impact of the 21-year-old, Sydney-headquartered organization—Australia's leading non-profit in brain cancer research and patient advocacy.

Key Points: 
  • The ringing of the bell coincides with the November incorporation, in Maryland, of Cure Brain Cancer Foundation America, Inc.
  • The past month also saw Cure Brain Cancer Foundation's first-ever participation in the annual meeting of the Society for Neuro-Oncology, the world's leading brain cancer oncology and clinical research association.
  • "Cure Brain Cancer Foundation funds our own innovators: cancer scientists, research-physicians and groundbreaking, innovative early-stage biotechnology companies.
  • Cure Brain Cancer Foundation is an Australia-based non-profit organization that is working globally to rapidly improve disease survival through funding innovative brain cancer research.

Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion

Retrieved on: 
Friday, December 2, 2022

NEW YORK, Dec. 2, 2022 /PRNewswire/ -- Cure Brain Cancer Foundation CEO Lance Kawaguchi rang the bell to open trading on the Nasdaq stock exchange on Friday morning, December 2. The Foundation announced the establishment of an independent U.S. affiliate that will widely increase the impact of the 21-year-old, Sydney-headquartered organization—Australia's leading non-profit in brain cancer research and patient advocacy.

Key Points: 
  • The ringing of the bell coincides with the November incorporation, in Maryland, of Cure Brain Cancer Foundation America, Inc.
  • The past month also saw Cure Brain Cancer Foundation's first-ever participation in the annual meeting of the Society for Neuro-Oncology, the world's leading brain cancer oncology and clinical research association.
  • "Cure Brain Cancer Foundation funds our own innovators: cancer scientists, research-physicians and groundbreaking, innovative early-stage biotechnology companies.
  • Cure Brain Cancer Foundation is an Australia-based non-profit organization that is working globally to rapidly improve disease survival through funding innovative brain cancer research.

EQS-News: BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

Retrieved on: 
Friday, December 2, 2022

BriaCells lead candidate Bria-IMT is marketed as an off-the-shelf personalized cellular approach to immunotherapy for the treatment of advanced solid tumors.

Key Points: 
  • BriaCells lead candidate Bria-IMT is marketed as an off-the-shelf personalized cellular approach to immunotherapy for the treatment of advanced solid tumors.
  • The targeted patients are advanced breast cancer patients or terminal breast cancer patients.
  • BriaCell also reports it is currently developing next-generation off-the-shelf personalized immunotherapies targeting patients with advanced breast cancer and advanced prostate cancer.
  • Bria-OTS+, for advanced breast cancer, and Bria-PROS, for advanced prostate cancer, are designed to activate nave T cells and produce a strong immune response in patients.

The Banker magazine names Scotiabank Canada's Bank of the Year and gives global recognition to ScotiaRISE with the 2022 Banking in the Community Award

Retrieved on: 
Friday, December 2, 2022

TORONTO, Dec. 2, 2022 /CNW/ - Scotiabank announced today that it has been named Bank of the Year in Canada by The Banker magazine and has also received The Banker's global award for Banking in the Community.

Key Points: 
  • TORONTO, Dec. 2, 2022 /CNW/ - Scotiabank announced today that it has been named Bank of the Year in Canada by The Banker magazine and has also received The Banker's global award for Banking in the Community.
  • We are also exceedingly proud that our ScotiaRISE program has been recognized for the real and positive impact it is having on the communities we serve.
  • Notable highlights from this year's recognition include:
    The launch and expansion of the Scene+ loyalty program, which brings together SCENE and Scotia Rewards.
  • To date, ScotiaRISE has supported more than 200 community partners and provided more than $60 million in community investments globally.

Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician Recruitment and Retention

Retrieved on: 
Friday, December 2, 2022

As a Certified B Corporation, Chiesi deepens ASHP partnership to fund educational efforts designed to address the pharmacy technician shortage and support pharmaceutical professionals.

Key Points: 
  • As a Certified B Corporation, Chiesi deepens ASHP partnership to fund educational efforts designed to address the pharmacy technician shortage and support pharmaceutical professionals.
  • CARY, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), today announced its sponsorship of the ASHP (American Society of Health-System Pharmacists) Advantage initiative to support pharmacy technician recruitment and retention.
  • The ASHP Advantage initiative is designed to address the pharmacy technician shortage through educational strategies, tools and resources to improve recruitment and retention efforts.
  • Launch of the Pharmacy Technician Recruitment and Retention Resource Center, which will include detailed information about the initiative, a checklist of recruitment and retention strategies to assist pharmacists in their efforts, examples of career ladders for pharmacy technicians, and other resources.